185 related articles for article (PubMed ID: 8836386)
21. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
22. The value of serum bcl-2 levels in advanced epithelial ovarian cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2006; 23(2):213-7. PubMed ID: 16720921
[TBL] [Abstract][Full Text] [Related]
23. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
24. CA125 response: can it replace the traditional response criteria in ovarian cancer?
Guppy AE; Rustin GJ
Oncologist; 2002; 7(5):437-43. PubMed ID: 12401906
[TBL] [Abstract][Full Text] [Related]
25. Tissue polypeptide-specific antigen (TPS) as tumour marker in epithelial ovarian cancer.
Blokkebak-Poulsen J; Mogensen O; Mogensen B
Acta Oncol; 1997; 36(4):433-5. PubMed ID: 9247106
[No Abstract] [Full Text] [Related]
26. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
27. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I; Rustin GJ; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MK; Friedlander M; Jakobsen A; Vermorken JB
J Natl Cancer Inst; 2000 Sep; 92(18):1534-5. PubMed ID: 10995813
[No Abstract] [Full Text] [Related]
28. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not.
Dorizzi RM; Meneghelli S; Rocca M; Ferrari A
Clin Chem Lab Med; 2006; 44(11):1386-7; author reply 1388. PubMed ID: 17087656
[No Abstract] [Full Text] [Related]
29. Ovarian fibroma with marked ascites and elevated serum levels of CA-125 in a young girl.
Sugiyama A; Urushihara N; Fukumoto K; Fukuzawa H; Nagae H; Watanabe K; Mitsunaga M; Hasegawa S; Koyama M
J Pediatr Surg; 2011 May; 46(5):1001-4. PubMed ID: 21616270
[TBL] [Abstract][Full Text] [Related]
30. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
Burch D; Metcalfe S; Gallagher G; al-Azzawi F; Wheeler T
Eur J Gynaecol Oncol; 1994; 15(5):352-8. PubMed ID: 7828604
[No Abstract] [Full Text] [Related]
31. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
Lukácskó I; Hernádi Z; Sápy T; Borsos A
Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
[TBL] [Abstract][Full Text] [Related]
32. [Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
Bocheva Y; Bochev P; Ivanov S
Akush Ginekol (Sofiia); 2015; 54(1):11-7. PubMed ID: 25909124
[TBL] [Abstract][Full Text] [Related]
33. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
[TBL] [Abstract][Full Text] [Related]
34. Limitations to the use of the CA-125 antigen level in ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066
[No Abstract] [Full Text] [Related]
35. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
37. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
38. An unusual abdominal cystic mass.
Montaruli E; Branchereau S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):641; answer 642. PubMed ID: 23018573
[TBL] [Abstract][Full Text] [Related]
39. Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors.
Salonen J; Leminen A; Stenman UH; Butzow R; Heikinheimo M; Heikinheimo O
Tumour Biol; 2008; 29(1):50-6. PubMed ID: 18497549
[TBL] [Abstract][Full Text] [Related]
40. Designing early detection programs for ovarian cancer.
Hartge P
J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
